Please use this identifier to cite or link to this item:
https://hdl.handle.net/11499/30502
Title: | Effects of ankaferd hemostat on helicobacter pylori strains and antibiotic resistanc | Authors: | Çiftçiler, R. Koluman, A. Haznedaroğlu, İ.C. Akar, N. |
Keywords: | Ankaferd blood stopper Gastrointestinal bleeding Helicobacter pylori amoxicillin ankaferd clarithromycin hemostatic agent metronidazole unclassified drug ankaferd blood stopper antiinfective agent plant extract antibacterial activity antibiotic resistance antibiotic sensitivity Article bacterium identification bacterium isolation controlled study disk diffusion drug efficacy drug response gastritis Helicobacter infection human nonhuman RNA sequence stomach ulcer drug effect gastrointestinal disease microbial sensitivity test microbiology Anti-Bacterial Agents Drug Resistance, Bacterial Gastrointestinal Diseases Helicobacter Infections Humans Microbial Sensitivity Tests Plant Extracts |
Publisher: | Turkiye Klinikleri Journal of Medical Sciences | Abstract: | Background/aim: Ankaferd hemostat (ABS; Ankaferd blood stopper, İstanbul, Turkey) is a folkloric medicinal plant extract. The aim of this study was to determine the effect of Ankaferd hemostat (ABS) on the fate of Helicobacter pylori strains. The study also aims to determine alterations in the antimicrobial resistance of three different H. pylori strains in response to ABS exposure. Materials and methods: H. pylori Strain 1 was obtained from the culture collection ATCC 43504 and passaged three times for viability. Strain 2 was isolated from a gastric ulcer patient and Strain 3 was isolated from a gastritis patient. 1% of ABS was added to all of the strains and antimicrobial susceptibility was observed on 30 and 60 min after application. Results: The efficacy of ABS solutions in achieving significant logarithmic reduction in foodborne pathogens of H. pylori was observed in this study. This study showed that ABS has antibacterial (Anti-H. pylori) effects. Conclusion: Our present study indicated, for the first time, that ABS could act against H. pylori. ABS is clinically used for the management of GI bleeding due to benign and malignant GI lesions. Thus, the possible anti-H. pylori effect of ABS shall expand the therapeutic spectrum of the drug in GI lesions in relation to H. pylori infection such as peptic ulser disease (PUD) and lymphoid tissue (MALT) lymphomagenesis. © TUBİTAK. | URI: | https://hdl.handle.net/11499/30502 https://doi.org/10.3906/sag-1807-206 |
ISSN: | 1300-0144 |
Appears in Collections: | PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection Teknoloji Fakültesi Koleksiyonu TR Dizin İndeksli Yayınlar Koleksiyonu / TR Dizin Indexed Publications Collection WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection |
Files in This Item:
File | Size | Format | |
---|---|---|---|
sag-49-1-51-1807-206.pdf | 203.03 kB | Adobe PDF | View/Open |
CORE Recommender
SCOPUSTM
Citations
7
checked on Oct 13, 2024
WEB OF SCIENCETM
Citations
7
checked on Nov 21, 2024
Page view(s)
46
checked on Aug 24, 2024
Download(s)
10
checked on Aug 24, 2024
Google ScholarTM
Check
Altmetric
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.